Yantai Lnc Biotechnology Singapore Pte. Ltd.

This early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main …

This early-phase trial tested a new radioactive imaging agent called 18F-LNC1007 in 8 people—some healthy and some with a few small tumors. The goal was to see how the agent moves through the body, how much radiation it gives off, and whether it is safe. Participants received one…

This early-phase trial tested a single injection of a radioactive imaging agent called 68Ga-LNC1007 in 8 adults (healthy volunteers and solid tumor patients). The goal was to check its safety, how it moves through the body, and how well it shows up on scans. The study is already …